Evidence map›Paper›PMID 41242398›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

Longitudinal Trends in Myocardial Metabolic Uptake Following Stereotactic Arrhythmia Radioablation Using 2-Deoxy-2-[

Gerard M Walls, Geoffrey D Hugo, Rugheed Ghadban, Ali Javaheri, Kaitlin M S Moore, Pamela K Woodard, Richard LaForest, Scott M Bugenhagen, Nels C Knutson, Daniel H Cooper and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gerard M WallsDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri; Johnston Cancer Research Centre, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. Electronic address: gwalls@wustl.edu.
Geoffrey D HugoDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Rugheed GhadbanDepartment of Medicine, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Ali JavaheriDepartment of Medicine, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Kaitlin M S MooreDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Pamela K WoodardDepartment of Radiology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Richard LaForestDepartment of Radiology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Scott M BugenhagenDepartment of Radiology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Nels C KnutsonDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Daniel H CooperJohnston Cancer Research Centre, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Stacey L RentschlerDepartment of Medicine, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Pamela P SamsonDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Clifford G RobinsonDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Phillip S CuculichDepartment of Medicine, Washington University School of Medicine in St Louis, Saint Louis, Missouri.
Carmen BergomDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, Saint Louis, Missouri.

Funding

Genetic Modifiers of Radiation Therapy-Induced CardiotoxicityR01HL147884 · NHLBI · WASHINGTON UNIVERSITY · PI BERGOM, CARMEN · 2019 to 2023
$2.3M
NHLBI NIH HHS R01 HL147884
6 · The paper itself

Abstract

purposeVentricular tachycardia (VT) is a life-threatening rhythm disturbance of the heart that has been shown to be amenable to treatment with stereotactic body radiation therapy, known as stereotactic arrhythmia radioablation (STAR). The metabolic impact of directly targeting arrhythmogenic regions of scarred left ventricle (LV) is unknown. In this study, the relationship between radiation dose and 2-deoxy-2-[ METHODS AND MATERIALS: Patients with VT in the ENCORE-VT trial received a 25 Gy single-fraction of STAR to an electrophysiology guided target volume planned on 4-dimensional computed tomography (CT). Patients underwent

resultsNineteen patients received STAR. Median VT episodes were reduced from 119 in the 6 months before versus 3 in the 6 months after STAR (P < .001). Targeted LV segments had lower baseline

conclusionsIn this small hypothesis-generating study, late SUV increases (day 90) were observed in targeted segments, consistent with VT burden reduction. Further longitudinal studies with

Indexed as

Fluorodeoxyglucose F18MyocardiumPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRadiosurgeryTachycardia, VentricularAgedFemaleHeartHeart VentriclesHumansMagnetic Resonance ImagingMaleMiddle AgedRadiotherapy DosageFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID41242398
PMCPMC13360421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.